secwatch / observer

8-K filed October 28, 2021, 7:59 PM ET ticker SABS CIK 0001833214

M&A confidence high sentiment neutral materiality 0.85

SAB Biotherapeutics completes de-SPAC merger; OLD SAB valued at $300M

SAB Biotherapeutics, Inc.

OLD SAB equity value set at $300M; conversion rate $10.10 per share.
Holders of 8,030,289 BCYP shares redeemed for ~$81.1M at ~$10.10/share.
Approximately $21.9M released to Company upon closing; $13.1M escrowed with Radcliffe.
Post-merger shares outstanding: 43,474,779; additional 12M earnout shares tied to stock price milestones.
Board set at 7 members; CFO Russell Beyer gets new employment agreement ($300K base, stock options).

item 1.01 item 2.01 item 9.01 item 3.02 item 4.01 item 5.03 item 5.01 item 5.02 item 5.06

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey G. Spragens

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Jeffrey G. Spragens 79 Class II Director

Appointed

William Polvino

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

William Polvino, MD 61 Class I Director

Appointed

Christine Hamilton

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Christine Hamilton, MBA 65 Class III Director

Appointed

Thomas Luke

Chief Medical Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Thomas Luke, MD 59 Chief Medical Officer

Appointed

Samuel J. Reich

Executive Chairman

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Samuel J. Reich 46 Class III Director and Executive Chairman of the Board

Departed

Samuel J. Reich

Executive Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

Appointed

Charles H. Randall, Jr.

Chief Strategy Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Charles H. Randall, Jr., MBA 58 Chief Strategy Officer

Departed

Ilan Katz

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

Appointed

Eddie J. Sullivan

President and Chief Executive Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Eddie J. Sullivan, PhD 55 Class III Director, President and Chief Executive Officer

Appointed

David Link

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

David Link 66 Class II Director

Appointed

Mervyn Turner

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Mervyn Turner, PhD 74 Class I Director

Departed

James Martin

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

Appointed

Russell Beyer

Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Russell Beyer 66 Chief Financial Officer

Departed

Stephen D. Collins

Director

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Jeffrey G. Spragens was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Jeffrey G. Spragens 79 Class II Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

William Polvino was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

William Polvino, MD 61 Class I Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Christine Hamilton was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Christine Hamilton, MBA 65 Class III Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Thomas Luke was appointed as Chief Medical Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Thomas Luke, MD 59 Chief Medical Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Samuel J. Reich was appointed as Executive Chairman at SAB Biotherapeutics, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

Samuel J. Reich 46 Class III Director and Executive Chairman of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel J. Reich departed as Executive Officer at SAB Biotherapeutics, Inc..

Action: ceased
Role: Executive Officer

Exact text from the filing

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Charles H. Randall, Jr. was appointed as Chief Strategy Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Strategy Officer

Exact text from the filing

Charles H. Randall, Jr., MBA 58 Chief Strategy Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ilan Katz departed as Director at SAB Biotherapeutics, Inc..

Action: ceased
Role: Director

Exact text from the filing

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Eddie J. Sullivan was appointed as President and Chief Executive Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Eddie J. Sullivan, PhD 55 Class III Director, President and Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

David Link was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

David Link 66 Class II Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Mervyn Turner was appointed as Director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Mervyn Turner, PhD 74 Class I Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Martin departed as Director at SAB Biotherapeutics, Inc..

Action: ceased
Role: Director

Exact text from the filing

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Russell Beyer was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Russell Beyer 66 Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen D. Collins departed as Director at SAB Biotherapeutics, Inc..

Action: ceased
Role: Director

Exact text from the filing

Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-026649

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.